#USA #Fort Lauderdale #Wound Care #MolecuLight #CAMPS 2025

MolecuLight Showcases Advanced Wound Care Imaging at the 2025 CAMPS Meeting

MolecuLight Inc., a pioneering company in fluorescence imaging devices for wound care, participated in the 2025 Cellular, Acellular, and Matrix-like Products Summit (CAMPs) held from February 28 to March 2 in Fort Lauderdale, Florida. At booth #21, MolecuLight presented its cutting-edge technology designed to enhance the assessment, measurement, documentation, and treatment decision-making processes related to wound care, particularly in light of the newly proposed language for local coverage determination (LCD) concerning skin substitutes.

The fluorescence imaging capabilities of MolecuLight enable clinicians to instantly visualize harmful bacterial loads in infected wounds and wounds prone to failure with skin substitutes. This real-time information empowers healthcare providers to treat patients more effectively, leading to quicker wound closures and improved patient outcomes. MolecuLight devices facilitate targeted therapies that optimize wound management strategies based on immediate, actionable insights.

Anil Amlani, CEO of MolecuLight, emphasized the critical need for their technology in wound treatment. "Our technology allows clinicians to see what they could not otherwise visualize. By identifying the presence of bacteria, we can significantly enhance the effectiveness of advanced therapies such as CAMPs, improving patient outcomes and ultimately reducing the burden of chronic wounds."

The newly proposed LCD for skin substitutes highlights the necessity for thorough evaluation and documentation of wounds. MolecuLight's comprehensive imaging and measurement devices directly address these requirements by providing:

• - Objective and visual evidence of the wound's condition.
• - Automated and precise measurements of the wound.
• - Enhanced documentation to justify the medical necessity of advanced therapies.

Amlani added, "MolecuLight’s ability to provide objective data in real time aligns perfectly with evolving guidelines for documentation and wound treatment. We are excited to showcase how our technology can help healthcare providers meet the proposed LCD language requirements and ensure optimal patient care."

Visit MolecuLight at the 2025 CAMPS Meeting

Participants at the 2025 CAMPS meeting are invited to visit MolecuLight at booth #21 to experience the technology firsthand and learn more about its applications, not only with CAMPs but also across the entire continuum of wound care. Attendees are encouraged to join the small group session titled “How to Ensure Optimal Outcomes with CAMPs” on February 28 from 11:25 AM to 12:45 PM, where MolecuLight will be featured as an innovative technology that enhances bed preparation for optimal CAMP results.

About MolecuLight

MolecuLight Inc. is a global leader in medical imaging, producing and marketing the MolecuLight i:X® and DX™ wound imaging devices. These are the only FDA-approved Class II imaging devices capable of real-time detection of high bacterial loads in wounds while also providing precise digital measurements for comprehensive wound management, backed by solid clinical evidence, including over 100 peer-reviewed publications.

For sales, media inquiries, or more information, please contact:
Hunter Zudans
Marketing Director
MolecuLight Inc.
T. +1.484.682.7580
Email: [email protected]
Website: www.moleculight.com.